Maraviroc clinical pharmacology: Difference between revisions
Ahmed Zaghw (talk | contribs) (Created page with "__NOTOC__ {{Maraviroc}} {{CMG}}; {{AE}} {{AZ}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = SELZENTRY (MARAVIROC) TABLET, FILM COATED [PFIZER...") |
Ahmed Zaghw (talk | contribs) No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{AZ}} | {{CMG}}; {{AE}} {{AZ}} | ||
==Clinical Pharmacology== | |||
===Mechanism of Action=== | |||
Maraviroc is an antiviral drug. | |||
===Pharmacodynamics=== | |||
Exposure Response Relationship in Treatment-Experienced Subjects | |||
The relationship between maraviroc, modeled plasma trough concentration (Cmin) (1–9 samples per patient taken on up to 7 visits), and virologic response was evaluated in 973 treatment-experienced HIV-1-infected subjects with varied optimized background antiretroviral regimens in studies A4001027 and A4001028. The Cmin, baseline viral load, baseline CD4+ cell count and overall sensitivity score (OSS) were found to be important predictors of virologic success (defined as viral load < 400 copies/mL at 24 weeks). Table 7 illustrates the proportion of subjects with virologic success (%) within each Cmin quartile for 150 mg twice daily and 300 mg twice daily groups.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = SELZENTRY (MARAVIROC) TABLET, FILM COATED [PFIZER LABORATORIES DIV PFIZER INC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a94a9a2b-337b-4c13-8622-fc392194dc21 | publisher = | date = | accessdate = }}</ref> | |||
==References== | ==References== | ||
Revision as of 16:15, 3 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Clinical Pharmacology
Mechanism of Action
Maraviroc is an antiviral drug.
Pharmacodynamics
Exposure Response Relationship in Treatment-Experienced Subjects
The relationship between maraviroc, modeled plasma trough concentration (Cmin) (1–9 samples per patient taken on up to 7 visits), and virologic response was evaluated in 973 treatment-experienced HIV-1-infected subjects with varied optimized background antiretroviral regimens in studies A4001027 and A4001028. The Cmin, baseline viral load, baseline CD4+ cell count and overall sensitivity score (OSS) were found to be important predictors of virologic success (defined as viral load < 400 copies/mL at 24 weeks). Table 7 illustrates the proportion of subjects with virologic success (%) within each Cmin quartile for 150 mg twice daily and 300 mg twice daily groups.[1]
References
Adapted from the FDA Package Insert.